( June 12, 2025, 2:33 PM EDT) -- WASHINGTON, D.C. — A Federal Circuit U.S. Court of Appeals panel on June 11 said there was no error in the U.S. Patent Trial and Appeal Board’s (PTAB) finding that all claims of a biotechnology company’s patents on gene modification are invalid; the panel said that substantial evidence supported PTAB’s finding that prior art anticipated the patents....